Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia

Current Neuropharmacology

Volumn 3, Issue 4, 2005, Pages 317-323

  Zhang, Yonghua ^a   Kimelberg, Harold K ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Adrenoceptor; Alpha 2 adrenergic agonist; Cerebral ischemia; Excitatory amino acids; Imidazoline receptor; Neuroprotection; Stroke; Sympathoinhibition

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DEXMEDETOMIDINE; DIZOCILPINE; IDAZOXAN; IMIDAZOLINE RECEPTOR; KAINIC ACID; NITRIC OXIDE SYNTHASE INHIBITOR; RILMENIDINE; TIZANIDINE;

BRAIN INJURY; BRAIN ISCHEMIA; CAUSE OF DEATH; CELL STRUCTURE; CLINICAL STUDY; DRUG HALF LIFE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN INDUCTION; REPERFUSION INJURY; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

EID: 26844454052     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015905774322534     Document Type: Review

References (81)

1. Alblas, J., van Corven, E.J., Hordijk, P.L., Milligan, G., Moolenaar, W.H. (1993) Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts. J. Biol. Chem., 268, 22235-22238.
2. Barron, K.D., Dentinger, M.P., Kimelberg, H.K., Nelson, L.R., Bourke, R.S., Keegan, S., Mankes, R., Cragoe, E.J. (1988) Ultrastructural features of a brain injury model in cat. I. Vascular and neuroglial changes and the prevention of astroglial swelling by a fluorenyl (aryloxy) alkanoic acid derivative (L-644,71 1). Acta Neuropathol (Berl.), 75, 295-307.
3. Berkman, M.Z., Zirh, T.A., Berkman, K., Pamir, M.N. (1998) Tizanidine is an effective agent in the prevention of focal cerebral ischemia in rats: An experimental study. Surg. Neurol., 50, 264-271.
4. Boehm, S. (1999) Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J. Physiol. (Lond.), 519, 439-449.
5. Bricca, G., Greney, H., Dontenwill-Kieffer, M., Zhang, J., Belcourt, A., Bousquet, P. (1993) Heterogeneity of the specific imidazoline binding of [3H]idazoxan in the human cerebral cortex. Neurochem. Int., 22, 153-63.
6. Bricca, G., Greney, H., Zhang, J., Dontenwill, M., Stutzmann, J., Belcourt, A., Bousquet, P. (1994) Human brain imidazoline receptors: further characterization with [3H]clonidine. Eur. J. Pharmacol., 266, 25-33.
7. Bylund, D.B., Eikenburg, D.C., Hieble, J.P., Langer, S.Z., Lefkowitz, R.J., Minneman, K.P., Molinoff, P.B., Ruffolo, R.R., Trendelenburg, U. (1994) International Union of Pharmacology Nomenclature on adrenoceptors. Pharmacol. Rev., 46, 121-136.
8. Bylund, D.B., Ray-Prenger, C. (1989) α2A and α2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor type. J. Pharmacol. Exp. Ther., 251, 640-644.
9. Callado, L.F., Stamford, J.A. (1999) Alpha2A- but not alpha2B/C-adrenoceptors modulate noradrenaline release in rat locus coeruleus: voltammetric data. Eur. J. Pharmacol., 366, 35-39.
10. Carpene, C., Collon, P., Remaury, A., Cordi, A., Hudson, A., Nutt, D., Lafontan, M. (1995) Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J. Pharmacol. Exp. Ther., 272, 681-688.
11. Choi, D.W. (1990) Limitations of in vitro models of ischemia. Prog. Clin. Biol. Res,, 361, 291-9.
12. Coupry, I., Atlas, D., Podevin, R.A., Uzielli, I., Parini, A. (1989) Imidazoline-guanidium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. J. Pharmacol. Exp. Ther., 252, 293-299
13. Docherty, J.R. (1998) Subtypes of functional alphal- and alpha2-adrenoceptors. Eur. J. Pharmacol., 361, 1-15.
14. Donello, J.E., Padillo, E.U., Webster, M.L., Wheeler, L.A., Gil, D.W. (2001) alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther., 296, 216-23.
15. 2 adrenergic agonists for regional anesthesia: A clinical review of clonidine (1984-1995). Anesthesiology, 86, 655-674.
16. Engelhard, K., Werner, C., Eberspacher, E., Bachl, M., Blobner, M., Hildt, E., Hutzler, P., Kochs, E. (2003) The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth. Analg., 96, 524-531.
17. Engelhard, K., Werner, C., Kaspar, S., Mollenberg, O., Blobner, M., Bachl, M., Kochs, E. (2002) Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology, 96, 450-457.
18. Ernsberger, P., Meeley, M.P., Mann, J.J., Reis, D.J. (1987) Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur. J. Pharmacol., 134, 1-43.
19. Ernsberger, P., Meeley, M.P., Reis, D.J. (1988) An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Res., 441, 309-318.
20. Farber, N.B., Foster, J., Duhan, N.L., Olney, J.W. (1995) alpha 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology, 12, 347-349.
21. Ferrendelli, J.A. (1978) Distribution and regulation of cyclic GMP in the central nervous system. Adv. Cyclic Nucleotide Protein Phosphorylation Res., 9, 453-464.
22. Fitzgerald, L.R., Mannan, I.J., Dytko, G.M., Wu, H.L., Nambi, P. (1999) Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay. Anal. Biochem., 275, 54-61.
23. Garcia-Sevilla, J.A., Sastre, M., Escriba, P.V. (1995) Age-dependent increases of immunoreactive imidazoline receptors in the human brain: possible association of a 29/30 kDa protein with the I2-imidazoline receptor identified by [3H]idazoxan. Neurosci. Lett., 184, 133-136.
24. Globus, M.Y., Busto, R., Dietrich, W.D., Martinez, E., Ginsberg, M.D. (1988) Intraischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemia. Neurosci. Lett., 91, 36-40.
25. Globus, M.Y., Busto, R., Dietrich, W.D., Martinez, E., Valdes, I., Ginsberg, M.D. (1989) Direct evidence for acute and massive norepinephrine release in the hippocampus during transient iscjemia. J. Cereb. Blood Flow Metab., 9, 892-896.
26. Goldstein, D.S. (1998) Catecholamine receptors and signal transduction. Adv. Pharmacol., 42, 379-390.
27. Gustafson, I., Miyauchi, Y., Wieloch, T.W. (1989) Postischemic administration of idazoxan, an alpha-2 adrenergic receptor antagonist, decreases neuronal damage in the rat brain. J. Cereb. Blood Flow Metab., 9, 171-174.
28. Gustafson, I., Westerberg, E., Wieloch, T. (1990) Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab., 10, 885-894.
29. Halonen, T., Kotti, T,, Tuunanen, J., Toppinen, A., Miettinen, R., Riekkinen, P. (1995) Alpha sub 2-adrenoceptor agonist dexmetedomidine, protects against kainic acid-induced convulsions and neuronal damage. Brain Res., 693, 217-224.
30. Hart, J.L., Jing, M., Bina, S., Freas, W., Van Dyke, R.A., Muldoon, S.M. (1993) Effects of halothane on EDRF/cGMP-mediated vascular smooth muscle relaxations. Anesthesiology, 79, 323-331.
31. Hein, L., Kobilka, B.K. (1995) Adrenergic receptor signal transduction and regulation. Neuropharmacology, 34, 357-366.
32. Hoffman, W.E., Cheng, M.A., Thomas, C., Baughman, V.L., Albrecht, R.F. (1991) Clonidine decrease plasma catecholamines and improves outcome from incomplete ischemia in the rat. Anesth. Anaig., 73, 460-464.
33. 2 - adrenergic antagonist atipamezole. Anesthesiology, 75, 328-332.
34. Huang, R., Chen, Y., Yu, A.C., Hertz, L. (2000) Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity. J. Cereb. Blood Flow Metab., 20, 895-898.
35. Jevtovic-Todorovic, V., Wozniak, D.F., Powell, S., Nardi, A., Olney, J.W. (1998) Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res., 781, 202-211.
36. Johns, R.A., Moscicki, J.C., DiFazio, C.A. (1992) Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia. Anesthesiology, 77, 779-784.
37. Jolkkonen, J., Puurunen, K., Koistinaho, J., Kauppinen, R., Haapalinna, A., Nieminen, L., Sivenius, J. (1999) Neuroprotection by the alpha 2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur. J. Pharmacol., 372, 31-36.
38. 2 - adrenergic agonists. Anethesiology, 93, 1345-1349.
39. Kamisaki, Y., Ishikawa, T., Takao, Y., Omodani, H., Kuno, N., Itoh, T. (1990) Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Res., 514, 15-21.
40. Kapinya, K.J., Lowl, D., Futterer, C., Maurer, M., Waschke, K.F., Isaev, N.K., Dirnagl, U. (2002) Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. Stroke, 33, 1889-1898.
41. Kim, H.K., Zornow, M.H,, Strnat, M.A., Maze, M. (1996) Dexmedetomidine does not attenuate increases in excitatory amino acids after transient global ischemia in the rabbit. J. Neurosurg. Anesthesiol., 8, 230-236.
42. Kimelberg, H.K. (2000) Cell volume in the CNS: regulation and implications for nervous system function and pathology. Neuroscientist, 6, 13-24.
43. Kimelberg, H.K. (2005) Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia, 50, 389-397.
44. Koyuncuoǧlu, H., Aricioǧlu, F., Üresin, Y., Dizdar, Y., Esin, Y. (1992) Effect of Tizanidine morphine physical dependence: attenuation and intensification. Pharmacol. Biochem. Behav., 42, 693-698.
45. Kuhmonen, J., Pokorny, J., Miettinen, R., Haapalinna, A., Jolkkonen, J., Riekkinen, P., Sivenius, J. (1997) Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology, 87, 371-377.
46. Lakhlani, P.P., Lovinger, D.M., Limbird, L.E. (1996) Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Mol. Pharmacol., 50, 96-103.
47. Lalies, M.D., Hibell, A., Hudson, A.L., Nutt, D.J. (1999) Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands. Ann. NY Acad. Sci., 881, 114-117.
48. Langer, S.Z. (1980) Presynaptic regulation of the release of catecholamines. Pharmacol. Rev., 32, 337-362.
49. Laudenbach, V., Mantz, J., Lagercrantz, H., Demonts, J., Evrard, P., Gressens, P. (2002) Effects of α2-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine, Anesthesiology, 96, 134-141.
50. MacDonald, E., Scheinin, H., Scheinin, M. (1988) Behavioral and neurochemical effects of metedomidine, a novel veterinary sedative. Eur. J. Pharmacol., 158, 119-127.
51. Maeda-Hagiwara, M., Watanabe, H., Kanaoka, R., Watanabe, K. (1986) Influence of clonidine and a new related imidazoline derivative (Tizanidine) on rat gastric mucosa. Pharmacology, 32, 109-113.
52. Maier, C., Steinberg, G.K., Sun, G.H., Zhi, G.T., Maze, M. (1993) Neuroprotection by the (alpha sub 2-adrenoceptor agonist dexmetedomidine in a focal model of cerebral ischemia. Anesthesiology, 79, 306-312.
53. Maiese, K., Pek, L., Berger, S.B., Reis, D.J. (1992) Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J. Cereb. Blood Flow Metab., 12, 53-63.
54. Maze, M., Tranquilli, W. (1991) Alpha-2 adrenoceptor agonists: Defining the role in clinical anesthesia. Anesthesiology, 74, 581-605.
55. Meyer, J.S., Welch, K.M., Okamoto, S., Shimazu, K. (1974) Disordered neurotransmitter function. Brain, 97, 655-664.
56. Michel, M.C., Insel, P.A. (1989) Are there multiple imidazoline binding sites? Trends Pharmacol. Sci., 10, 342-344.
57. Michel, M.C., Regan, J.W., Gerhardt, M.A., Neubig, R.R., Insel, P.A., Motulsky, H.J. (1990) Nonadrenergic [3H]idazoxan binding sites are physically distinct from alpha 2-adrenergic receptors. Mol. Pharmacol., 37, 65-68.
58. Mongin, A.A., Kimelberg, H.K. (2005) Astrocytic swelling in neuropathology. In: Kettenmann, H.O. and Ransom, B.R. Eds, Neuroglia. New York, Oxford University Press. pp. 550-562.
59. Mori-Okamoto, J., Namii, Y., Tatsuno, J. (1991) Subtypes of adrenergic receptors and intracellular mechanisms involved in modulatory effects of noradrenaline on glutamate. Brain Res., 539, 67-75.
60. Muir, K.W., Lees, K.R. (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke, 26, 503-513.
61. 2 - adrenergic agonist dexmedetomidine in the locus coerulerus of the rat. Anesthesiology, 81, 1527-1534.
62. Nakamura, K., Mori, K. (1993) Nitric oxide and anesthesia. Anesth. Analg., 77, 877-879.
63. Nishigaya, K., Yoshida, Y., Sasuga, M., Nukui, H., Ooneda, G. (1991) effect of recirculation on exacerbation of ischemic vascular lesions in rat brain. Stroke, 22, 165-204.
64. Oliet, S.H., Piet, R., Poulain, D.A. (2001) Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science, 292, 923-926.
65. Ozog, M.A., Wilson, J.X., Dixon, S.J., Cechetto, D.F. (1998) Rilmenidine elevates cytosolic free calcium concentration in suspended cerebral astrocytes. J. Neurochem., 71, 1429-1435.
66. Parini, A., Moudanos, C.G., Pizzinat, N., Lanier, S.M. (1996) The elusive family of imidazoline binding sites. Trends Pharmacol. Sci., 17, 13-16.
67. Reis, D.J., Regunathan, S., Golanov, E.V., Feinstein, D.L. (1994) Protection of focal ischemic infarction by rilmenidine in the animal: evidence that interactions with central imidazoline receptors may be neuroprotective. Am. J. Cardiol., 74, 25A-30A.
68. Reis, D.J., Regunathan, S., Wang, H., Feinstein, D.L., Meeley, M.P. (1992) Imidazoline receptors in the nervous system. Fundam. Clin. Pharmacol., 6, 23S-29S.
69. Scanziani, M., Gahwwiler, B.H., Thompson, S.M. (1993) Presynaptic inhibition of excitatory transmission mediated by alpha adrenergic receptors in area Ca3 of the rat hippocampus in vitro. J Neurosci., 13, 5393-5401.
70. Siesjö, B.K. (1988) Mechanisms of ischemic brain damage. Crit. Care Med., 16, 954-963.
71. Siesjo, B.K., Bengtsson, F. (1989) Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J. Cereb. Blood Flow Metab., 9, 127-140.
72. Somjen, G.G. (2002) Ion regulation in the brain: implications for pathophysiology. Neuroscientist, 8, 254-267.
73. Starke, K. (1987) Presynaptic alpha autoreceptors. Rev. Physiol. Biochem. Pharmacol., 107, 74-146.
74. Summers, R.J., McMartin, L.R. (1993) Adrenoceptors and their second messenger systems. J. Neurochem., 60, 10-23.
75. Surprenant, A., Horstman, D.A., Akbarali, H., Limbird, L.E. (1992) A point mutation of alpha 2 -adrenoceptor that blocks coupling to potassium but not calcium currents. Science, 257, 977-980.
76. Szabo, B. (2002) Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol. Therap., 93, 1-35.
77. Talke, P., Bickler, P.E. (1996) Effects of dexmetedomide on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology, 85, 551-557.
78. 2 - adrenoceptor agonists decrease cyclic guanosine 3′,5′-monophosphate in the mouse brain. Anesthesiology, 85, 544-550.
79. Weinberger, R., Nieves-Rosa, J. (1988) Monoamine neurotransmitters in the evolution of infarction in ischemic striatum: morphologic correlation. J. Neural Trans., 71, 133-142.
80. Wikberg, J.E., Uhlen, S. (1990) Further characterization of the guinea pig cerebral cortex idazoxan receptor: solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug. J. Neurochem., 55, 192-203.
81. Zhang, Y. (2004) Clonidine preconditioning decreases brain infarct sizes and improves neurological outcome from transient forebrain ischemia in the rat. Neuroscience, 125, 625-631.